PLK1 and colorectal carcinoma: These findings collectively confirm that CDC7 is a crucial downstream effector of PLK1 for cell survival upon oxaliplatin treatment and that targeting the PLK1‐MYC‐CDC7 axis can enhance oxaliplatin‐based chemotherapy regimens in CRC.